Chirata (Swertia chirayita): A Comprehensive Reference
1. Identity and Botanical Description
Scientific Nomenclature and Taxonomy
Chirata is scientifically designated Swertia chirayita (Roxb.) H. Karst., a traditionally used, well-recognized medicinal plant of the family Gentianaceae with significant therapeutic potential. The species has accumulated a number of synonyms over its taxonomic history: it has been remarked upon in biography as Ophelia chirata, Agathotes chirayita, and Gentiana chirayita. It was first described by Roxburgh under the name Gentiana chyrayta in 1814.
Common Names
The plant is known by an array of names: Anaryatikta, Bhunimba, Chiratitka, and Kairata in Sanskrit; Qasabuzzarirah in Arabic and Farsi; Chiaravata in Urdu; Sekhagi in Burma; and Chirrato or Chiraita in Nepal. In Ayurveda, the ancient medical science of India, it has been mentioned as Kiraata, whereas Unani medicine has recorded it as Chiraitaa. Chirata is sometimes known as "Nepali neem," since it is common in forests of Nepal. The name "Chirayita" itself derives from the Sanskrit "Kiratatikta," where "Kirata" refers to people from the Himalayan region and "tikta" means bitter.
Botanical Description
S. chirayita is a critically endangered medicinal herb that grows at high altitudes in the sub-temperate regions of the Himalayas between 1200 and 2100 m altitude, from Kashmir to Bhutan, on the slopes of moist shady places. Some authors have described S. chirayita as an annual, while others characterize it as biennial or pluri-annual. It is an annual or biennial herb that grows 0.6–1.5 m tall, with an erect stem about 2–3 feet long, the middle portion cylindrical and the upper portion quadrangular with prominent decurrent lines at each angle. The stem is orange-brown or purplish in color with large continuous yellowish pith. Leaves are lanceolate, in opposite pairs, sessile, acuminate, cordate at the base, five- to seven-nerved, and approximately 4 cm long. The root is simple, yellowish, tapering, and short, almost 7–8 cm long. Flowers are small, numerous, tetramerous, arranged in large leafy panicles, green-yellow, and tinged with purple and green or white hairs.
Geographical Distribution
The species is native to the temperate Himalayas and Khasi hills of Meghalaya, found at altitudes of 1100 m to 3000 m. S. chirayita inhabits the challenging terrains and high altitudes of the Himalayas across Pakistan, India, Nepal, Bhutan, and Tibet. Related species, Swertia japonica and Swertia pseudochinensis, are found in Japan and China, respectively.
Part Used
The whole plant of S. chirayita is used in traditional medicine. Specifically, the entire aerial parts — particularly the dried stem and leaves — serve as the primary material for commercial and pharmaceutical preparations. The root has also been employed in some traditional applications, particularly decoctions.
2. Pharmacopeial Recognition and Official Status
This plant is documented in the Ayurveda, Indian pharmacological codex, Unani, Siddha, American, and British pharmacopoeias, and several traditional medicinal systems. In 1839, it was included in the Edinburgh Pharmacopoeia, marking its early recognition in Western medicine. Swertia chirayita is used in British and American pharmacopoeias as tinctures and infusions. As highlighted by the National Medicinal Plant Board, Government of India, Swertia chirata is among the 32 priority medicinal herbs in the biodiversity of Uttarakhand, India.
3. Traditional and Historical Use
Ayurveda
The earliest recorded use appears in the Charaka Samhita Sutra (3rd to 2nd century BCE), where the species is recommended for reducing fever (jvaraghna) and purifying breast milk (stanyasodhana). The herb is well-reputed for its multifarious therapeutic values since the era of the Atharvaveda. In Ayurveda, Swertia chirata is described as bitter (tikta) in taste, with a thermal action defined as cooling (shita), easily digestible (laghu), and dry (ruksha).
In India, it is traditionally used as a bitter tonic to stimulate appetite, as a febrifuge, also used against asthma and liver disorders, and is reported to stop internal hemorrhage of the stomach when taken with sandalwood paste. A concoction of chirata with cardamom, turmeric, and kutki is prescribed for gastrointestinal infections, and combined with ginger it is considered useful for fever.
Unani Medicine
Fundamentally, Swertia chirayita is a conventional medicinal plant used in the Unani system of medicine. Various Unani medicine formulations incorporate the plant, including tablets, capsules, syrups, and semi-solid preparations. In Unani classification, the plant is known as Chiraitaa, and its principal application is as a bitter tonic, antipyretic, and remedy for hepatic complaints.
Siddha and Tibetan Medicine
The medicinal efficacy of S. chirayita is officially registered and recognized in the Indian pharmaceutical codex, the British Pharmacopoeia, and in different Indian traditional systems of medicines such as Ayurveda, Unani, Siddha, and Tibetan medicine. In the Tibetan system, related Swertia species have been employed for fever management, and the plant is recognized across the trans-Himalayan medical traditions.
Preparations and Household Uses
For tremor fever, the traditional preparation involves cutting the whole S. chirayita plant into small pieces and boiling them in half a litre of water until the volume is reduced to less than half a glass. The filtered water is stored in a glass bottle; half a spoon is given to children once a day for two days, while the adult posology is one spoon once per day for two days. The whole plant is also boiled in water and one cup of decoction is taken orally to cure malaria; a paste of the plant is applied topically to treat skin diseases such as eczema and pimples.
As a household remedy, the whole plant is dipped in water overnight and the bitter juice is taken in the morning to treat malarial fever.
Range of Traditional Indications
Traditional uses encompass fever, vomiting, jaundice, digestive disorders, heart diseases, diabetes, malaria, scorpion bite, and skin diseases. The whole plant is widely used as a folk medicine in the treatment of general weakness, fever, cold, joint pain, asthma, headache, hypertension, edema, skin diseases, liver disorders, stomach disorders, intrinsic hemorrhage, and vomiting.
Formulations in Classical Systems
The plant is used in the preparation of branded herbal drugs such as Diabegon, D-400, Chirayita tablet, GlucoBuster, DBCare, Himoliv, and Melicon V, and is one of the ingredients in Ayurvedic formulations such as Kabdeen (for treating viral hepatitis) and Sudarshan churna.
4. Key Phytochemical Constituents
Overview of Chemical Classes
Approximately 123 specialized metabolites — including xanthones, seco-iridoids, terpenoids, alkaloids, and flavonoids — have been isolated and characterized from S. chirayita. The wide-range biological activities of S. chirayita are attributed to a diverse group of pharmacologically bioactive compounds belonging to different classes such as xanthones and their derivatives, lignans, alkaloids, flavonoids, terpenoids, iridoids, secoiridoids, and other compounds such as chiratin, ophelic acid, palmitic acid, oleic acid, and stearic acid.
Primary Bioactive Compounds
Xanthones (mangiferin, bellidifolin, swertianin) and seco-iridoid glycosides (amarogentin, amaroswerin, sweroside, gentiopicroside) are the main constituents of this medicinal plant. The pharmacological efficacy of S. chirayita has been partly attributed to the biological activity of major phytoconstituents including amarogentin, swertiamarin, mangiferin, swerchirin, sweroside, amaroswerin, and gentiopicrin.
- Amarogentin: This ethnomedicinal herb is known mostly for its bitter taste caused by the presence of different chemical constituents such as amarogentin — reported to be the most bitter compound isolated to date — along with swerchirin, swertiamarin, and other bioactive compounds that are directly associated with human health welfare. Amarogentin is a bitter secoiridoid glycoside and an activator of the human bitter taste receptor.
- Swertiamarin: A secoiridoid glycoside whose active metabolite gentianine is believed to contribute to antidiabetic activity. Swertiamarin is effective in gastric emptying and has gastrointestinal motility and antinociceptive activity.
- Mangiferin: Mangiferin, a potent phytoconstituent found in S. chirata, can exhibit antihyperglycemic potential by exhibiting glucosidase and DPPH radical inhibition action.
- Swerchirin: A xanthone constituent contributing to the plant's bitter taste and recognized as a major marker compound.
- Gentiopicrin (Gentiopicroside): A secoiridoid glycoside also present in the plant.
- Chiratin and Ophelic Acid: Among the identified compounds, chiratin and ophelic acid are responsible for the bitter nature of S. chirayita.
- Fatty Acids: Different fatty acids such as stearic acid, oleic acid, and palmitic acid have also been reported from this plant.
- Additional Phenolics: Plant extracts also contain quercetin, gallic acid, ferulic acid, and rutin, identified by HPLC analysis.
Metabolite Classes: Secoiridoids and Xanthones
S. chirayita contains two major classes of metabolites — secoiridoids and xanthones — specifically swertiamarin, mangiferin, amarogentin, and amaroswerin. Phytochemical screening confirmed the presence of a broader range of bioactive chemical constituents including steroids, tannins, phenolics, saponins, alkaloids, flavonoids, and glycosides.
5. Pharmacology and Mechanisms of Action
Antidiabetic / Hypoglycemic Mechanisms
Various in vivo and in vitro studies suggest that the biological activity of S. chirayita extracts and their active compounds can be attributed to multifactorial pharmacological effects and related physiological outcomes on insulin biology. Blood glucose–lowering potential of S. chirayita extracts is reported to be comparable to glibenclamide, metformin, and gliclazide in preclinical models of type 2 diabetes mellitus.
Gentianine, another antidiabetic compound of the plant and the active metabolite of swertiamarin, is believed to attribute to swertiamarin's efficacy. Promising amelioration in the adipogenesis-associated expression of PPAR-γ, GLUT-4, and adiponectin by gentianine administration has been reported as responsible for the antidiabetic efficacy of swertiamarin.
The existence of mangiferin in the plant's stem is considered mainly responsible for the plant's antidiabetic activity. Promising antidiabetic efficacy of S. chirayita with improved insulin secretion was reported during cell line–based evaluation using insulin secretion from monolayers of BRIN-BD11 clonal pancreatic cells.
Anti-inflammatory Mechanism
Amarogentin shows varied activity in several pathophysiological conditions, and experimental analysis has revealed that it downregulates cyclooxygenase-2 (COX-2) activity and helps to curtail skin carcinogenesis in mouse models. Computer-aided drug discovery methods have been used to unravel the COX-2 inhibitory mechanism of amarogentin and to investigate its selectivity for the inducible isoform over the constitutive one.
Hepatoprotective Mechanism
The crude extracts and chemical components isolated from S. chirayita have shown promising in vivo and in vitro biological properties including hepatoprotective effects. The mechanism of hepatoprotection has been investigated through multiple models. Anti-hepatotoxic activity was evident in all tested Swertia species against both carbon tetrachloride and paracetamol toxicants; however, Swertia purpurascens, S. chirata, S. paniculata, and S. cordata exhibited better activity compared with other species investigated.
Antileishmanial Mechanism
Pharmacologically, amarogentin has antibacterial, antihepatitis, anticholinergic, and chemopreventive activities; moreover, amarogentin has been demonstrated to have antileishmanial activity. The compound has been identified as an inhibitor of topoisomerase I from Leishmania donovani, representing a defined molecular target for its antiparasitic effect.
Antioxidant Mechanisms
Phytochemicals from methanolic and aqueous extracts of Swertia species have been analyzed; antioxidant potential was assessed by measuring total phenolic content, total flavonoid content, and free radical scavenging potential via the DPPH assay. The phenolic and xanthone constituents are considered the primary contributors to observed antioxidant activity.
Antimicrobial Mechanisms
The minimum inhibitory concentration (MIC) of Swertia chirayita leaf extract showing 100% inhibition was 0.13 mg, 0.36 mg, and 0.13 mg against Staphylococcus aureus, Bacillus subtilis, and Salmonella typhi, respectively.
6. Scientific Evidence by Area of Use
6.1 Diabetes and Blood Sugar Regulation
Evidence strength: Preliminary — preclinical and very limited human data.
The most promising phytoconstituents from S. chirayita identified for the management of type 2 diabetes mellitus are amarogentin, swertiamarin, sweroside, mangiferin, oleanolic acid, bellidifolin, and swerchirin.
A 30-day clinical study was conducted on 12 type 2 diabetic patients, finding that ingestion of S. chirayita in ground powder form caused a 14.5% reduction in blood glucose level. This is the most frequently cited human-level datum in the literature but remains a very small, non-blinded observational study without a comparator arm and does not constitute robust clinical evidence.
In an experimental trial with albino Wistar rats, the antidiabetic activity of S. chirayita plant extract was evaluated in comparison to the standard oral drug glibenclamide. More research efforts are considered necessary to understand the exact mechanisms of the compounds and to develop overall safety of such plant formulations, with the current review clearly representing antidiabetic properties of Swertia chirayita extract and strategies to strengthen its safety application on humans.
As a co-therapy with metformin and gliclazide, mangiferin has been reported to address renal injury symptoms due to diabetic neuropathy in preclinical models.
6.2 Liver Protection (Hepatoprotective Activity)
Evidence strength: Preclinical (animal and in vitro). No controlled human clinical trials identified.
Research into the ability of extracts of these plants to offer protection against acute hepatotoxicity induced by paracetamol (150 mg/kg) in Swiss albino mice found that oral administration of S. chirayita extract (100–200 mg/kg) offered significant dose-dependent protection against paracetamol-induced hepatotoxicity as assessed by biochemical and histopathological parameters.
Different solvent fractions of the methanolic plant extracts of Swertia chirayita were assessed for hepatoprotective activity by carbon tetrachloride–induced liver damage in rats. Pharmacological evaluations carried out using scientifically accepted controls and protocols have confirmed some of the ethnomedicinally claimed biological actions, particularly beneficial effects on hepatic cells.
Swertiamarin has been tested for its anti-hepatitis activity. Despite the convergence of preclinical hepatoprotective data, no randomized controlled trials in humans have been published as of the literature reviewed.
6.3 Antimalarial Activity
Evidence strength: Preclinical (in vitro and animal models). Widely used traditionally, limited clinical validation.
Plant extracts were evaluated for antimalarial activity using thin blood smears, followed by [35S]-methionine incorporation into parasite proteins; the results clearly suggest that plant extracts possess potent antimalarial activity. As a household remedy, the whole plant is dipped in water overnight and the bitter juice is taken in the morning to treat malarial fever. However, these findings are in vitro or based on animal models; no published clinical trials specifically testing chirata extracts in malarial patients have been identified in the peer-reviewed literature.
6.4 Anti-inflammatory Activity
Evidence strength: Preclinical and computational. No human clinical trials identified.
It has been described in medical research to reduce fever, ease headache, and decrease inflammation. The primary mechanism studied is COX-2 inhibition by amarogentin, which has been explored using molecular docking and in vitro cell models. The extract and isolated compounds exhibited a wide spectrum of pharmacological effects such as anti-inflammatory, antioxidant, antitumor, hepatoprotective, antiviral, antimalarial, and antibacterial activity, offering scientific evidence for traditional claims. Human trial evidence is absent for this indication.
6.5 Anticancer / Chemopreventive Activity
Evidence strength: Preliminary — cell line and animal studies only. No human trials.
Studies suggest that amarogentin acts on liver carcinogenesis and skin carcinogenesis and reduces tumor progression. Amarogentin is reported to be anticancerous. Amarogentin is a potent anticancer compound and an inhibitor of topoisomerase I as well as COX-2.
Recently reported anticancer effects of S. chirata have amplified its importance in the scientific community. However, all anticancer evidence currently resides at the in vitro and animal model level. No human clinical trials have been completed or published.
6.6 Antileishmanial Activity
Evidence strength: Preclinical animal and in vitro. No human trials identified.
The plant extract shows antileishmanial activity against Leishmania donovani in golden hamsters. Pharmacologically, amarogentin has been proven for its antileishmanial activity. The mechanism involves inhibition of topoisomerase I in Leishmania donovani.
6.7 Antioxidant Activity
Evidence strength: In vitro. No human trials identified.
Antioxidant potential of all extracts was assessed by measuring total phenolic content, total flavonoid content, and free radical scavenging potential via the DPPH assay, and antibacterial activity was assessed against various pathogenic and non-pathogenic bacteria in vitro by the Kirby-Bauer agar well diffusion method. The plant extracts consistently demonstrate notable free radical scavenging potential in laboratory settings; translation to human benefit is unproven.
6.8 Antimicrobial Activity
Evidence strength: In vitro. No human trials identified.
Reported pharmacological studies have demonstrated Swertia chirayita to exhibit anti-diabetic, anti-leishmanial, immunomodulatory, anti-malarial, anthelmintic, anti-pyretic, anti-inflammatory, hepatoprotective, anti-carcinogenic, antioxidant, and antimicrobial activities. Antimicrobial effects against bacterial pathogens have been demonstrated using standard disc diffusion methods in vitro, but no controlled human studies exist.
6.9 Central Nervous System Activity
Evidence strength: Animal studies only.
The CNS activity of swertiamarin, a secoiridoid glycoside isolated from Swertia chirata, has been evaluated; alcoholic extracts of chirata (excluding mangiferin) significantly reverse the mangiferin-induced CNS-stimulating effect in albino mice and rats. The results indicate that mangiferin and swertiamarin antagonize each other in vivo, thereby reversing their CNS effects. Isolated compounds have also been studied for behavioral effects, antidepressant activity, and anti-Parkinsonian activity in animal models.
6.10 Digestive and Gastric Activity
Evidence strength: Traditional use with some in vitro support. No human clinical trials identified.
Low doses or short-term use are traditionally considered good to stimulate the stomach and digestion, promote appetite, and stimulate bowel movement; traditional indications include indigestion, poor appetite, and flatulence. Swertiamarin is reported to be effective in gastric emptying and possesses gastrointestinal motility and antinociceptive activity in preclinical models.
7. Body Systems Associated with Chirata
- Hepatobiliary system: Hepatoprotective activity; traditionally used for jaundice, liver disorders, and hepatitis.
- Endocrine/Metabolic system: Antidiabetic and hypoglycemic activity via insulin secretion and glucose metabolism pathways.
- Immune system: Immunomodulatory activity reported in preclinical studies.
- Gastrointestinal system: Bitter tonic for appetite stimulation, digestive complaints, anthelmintic use, antidiarrheal effects.
- Cardiovascular system: Traditional use for hypertension and edema; cardiostimulant properties noted in the literature.
- Integumentary system: Topical and systemic use for skin diseases including eczema and inflammation.
- Central nervous system: Preclinical investigations of antidepressant and anti-Parkinsonian potential.
- Hematopoietic system: Traditional use as a blood purifier.
A broad compendium of activities has been reported for S. chirayita, including significant antibacterial, antioxidant, antidiabetic, anti-hepatitis B virus, anthelmintic, antimalarial, hypoglycemic, hepatoprotective, antifungal, cardiostimulant, anti-aging, antifatigue, antidiarrheal, anti-inflammatory, anti-pyretic, antiviral, anticholinergic, CNS depressant, anti-obesity, anti-adipogenic, antiatherosclerosis, antileishmanial, anti-ulcer, anti-hepatotoxic, analgesic, and gastroprotective activities.
8. Dosage Forms and Reported Doses
Traditional Preparations
Swertia chirayita is used in British and American pharmacopoeias as tinctures and infusions. An infusion of the herb is the preparation generally employed; it is also given as a tincture.
Traditional dose ranges recorded include: decoction 5–20 grams; powder 250 mg–3 grams.
Modern Dosage Forms
The plant is commercially available in multiple forms:
- Dried herbal powder: Used in decoctions or taken directly.
- Capsules and tablets: Standardized preparations marketed under various brand names.
- Tincture: Hydroalcoholic extracts prepared for Western herbal use.
- Liquid extracts: Used in polyherbal Ayurvedic syrups and formulations.
Doses Reported in Studies
Oral administration of S. chirayita extract at 100–200 mg/kg was used in the animal hepatoprotective study, offering significant dose-dependent protection against paracetamol-induced hepatotoxicity.
A 30-day clinical study in 12 type 2 diabetic patients used S. chirayita in ground powder form, resulting in a 14.5% reduction in blood glucose level. The specific dose used in this study was not fully specified in the available abstract.
In rabbit pharmacokinetic studies, mangiferin was characterized by relatively low clearance (approximately 0.14 L/h/kg) and a lesser volume of distribution (approximately 0.15 L/kg), while amarogentin exhibited rapid clearance (approximately 2.62 L/h/kg) and wide distribution (approximately 1.08 L/kg) from the systemic circulation.
9. Safety, Toxicology, and Drug Interactions
Overall Safety Profile
Despite its extensive historical usage in traditional herbal medicine, there is currently a scarcity of scientific evidence on the safety of S. chirayita. There is a lack of adequate information on the safety evaluation of the plant. Scientific gaps remain, including identification of bioactive compounds, structure-activity relationship and mechanistic action of isolated bioactive compounds, development of effective analytical methods for comprehensive quality control, and safety profiles that need to be addressed.
Hepatotoxicity Signal
In investigations on cellular growth of rat Reuber hepatoma cell line H4IIEC3/G−, except for the butanol extract of S. chirata, no other extracts exerted toxicity in terms of neutral red uptake by the cells. This suggests differential cytotoxic potential depending on extraction solvent and fraction. The safety of prolonged high-dose human use has not been formally evaluated in controlled studies.
Potential Drug Interactions
The methanol extract of S. chirata with antidiabetic activity contains mangiferin, amarogentin, amaroswerin, sweroside, and swertiamarin as active constituents; the pharmacokinetics of mangiferin and amarogentin have been studied after intravenous administration of pure standards and extract in rabbits to assess systemic interaction. Given the demonstrated hypoglycemic activity in preclinical models, an interaction risk with antidiabetic drugs (potentiation of glucose lowering) is pharmacologically plausible, though not formally established in human pharmacokinetic trials.
In animal studies, mangiferin and swertiamarin antagonize each other in vivo with respect to CNS effects, demonstrating that different phytochemical constituents can modulate each other's pharmacological activity. This raises the theoretical consideration that complex extract preparations may have unpredictable interactions with CNS-active medications.
Pregnancy and Special Populations
The safety of chirata in pregnancy and lactation has not been evaluated in controlled human studies. The traditional Ayurvedic pharmacopoeial category of the plant as having cooling and purifying properties is noted, but no systematic toxicology data for pregnant populations exists in the peer-reviewed literature.
10. Conservation Status and Adulteration
The increasing high usage of Swertia chirayita, mostly of underground tissues, combined with illegal overharvesting and habitat destruction has resulted in a drastic reduction of its populations, bringing this plant to the verge of extinction in the wild. The increasing national and international demand has led to unscrupulous collection from the wild and adulteration of supplies.
Due to its high demand and scarcity, several other species of Swertia — including S. alata, S. angustifolia, S. cordata, S. purpurascens, and S. paniculata — are being used as substitutes or adulterants for Swertia chirayita in India, Japan, China, Pakistan, and other Asian countries. Other identified adulterants and substitutes include species of Exacum, Slevolgia orientalis, and most commonly Andrographis paniculata.
Chirayita is enlisted in the IUCN list of endangered plant species. Quality control protocols to prevent misidentification and possible adulteration of S. chirayita are needed. Quality assessment methods using both targeted and non-targeted analytical tools are required to evaluate the quality of these highly-priced medicinal plants and their adulterants.
11. Evidence Gaps and Research Outlook
Scientific gaps remain in the identification of bioactive compounds, structure-activity relationships, and mechanistic action of isolated bioactive compounds, development of effective analytical methods for comprehensive quality control, and safety profiles.
Scientific validation of traditionally claimed medicinal potential is lacking for various bioactivities. Some of the bioactivities have been assessed using only extracts or fractions, creating a need for proper phytochemical studies to identify active constituents responsible for the specific bioactivity.
Although efficient micropropagation protocols have been established, further studies focusing on seed biology and ways of improving bioactive secondary metabolites in cultivated S. chirayita would be beneficial for their commercialization. Quality control protocols to prevent misidentification and possible adulteration are also needed.
In summary, reported pharmacological studies have demonstrated Swertia chirayita to exhibit anti-diabetic, anti-leishmanial, immunomodulatory, anti-malarial, anthelmintic, anti-pyretic, anti-inflammatory, hepatoprotective, anti-carcinogenic, antioxidant, and antimicrobial activities. However, the overwhelming majority of this evidence derives from in vitro and animal studies, with very few and methodologically limited human studies available. Robust, adequately powered, randomized controlled clinical trials are needed before any therapeutic claims can be substantiated at the level of modern evidence-based medicine.
References
Go back